FRT vs IDXX · rev $1.28B vs P/E 40, rev $2.36B
FRT (FRT) versus IDEXX Laboratories Inc (IDXX) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
FRT currently screens at market cap $0. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Not investment advice. Open the FRT and IDXX stock pages for the full models.
Not investment advice.